If you wait for FDA approval, it could be too late...

Breaking News: Pulitzer Prize nominated financial journalist reveals...

Dear Reader, Biotech can be one of the most rewarding sectors in the market. In fact, the list of 2024's best stocks is peppered with biotech names. Like Viking Therapeutics, up 210% this year alone. Or Arcutis Biotherapeutics, up 212% already in 2024. Janux Therapeutics is up 210% so far this year. But there's only one problem … Unless you have a PhD … Or an inside source … Good luck picking biotech winners ahead of time. The FDA approval process is extremely difficult. It can cost billions of dollars … And last more than a decade. Even then, after multiple phases of trials, a drug can still be rejected. In fact, 9 in 10 drugs never get approval from the FDA. They die on the vine. And even for the ones who survive, it can be hard to get any information on the status of a drug … Or how close it is to approval. The FDA is notoriously opaque. But for a special set of drug companies, all of that has changed. The FDA has started to quietly send out a signal. This signal means specific companies will get an expedited route to approval … And hands-on guidance from the FDA. For investors, there's something even more important going on here … Over 97% of the time the FDA sends out this signal … The company involved has seen its stock spike sometime in the following months. 74 out of 76 times since 2016. For an average gain of 117% in just eight months. And it has nothing to do with approval or rejection. Take Adaptimmune Therapeutics, for example. Shares were hovering around one dollar when the FDA sent out this quiet signal on Adaptimmune's new tumor drug. Within six months, the stock shot up 845%   It took almost four more years before the drug was approved. Caladrius Biosciences' stock was going nowhere, stuck around $4 … Then it got this FDA signal. And shares jumped 119% — in two days. The drug in question wasn't approved for another five years … Ocugen received an FDA signal in December 2023. Its share price spiked 435% in just five months. The drug has yet to be given final approval. It's a simple trade. The FDA sends out this signal. And 97% of the time the company's stock price has gone up in the following months. And whether the drug was eventually approved or not had no effect … Now, I believe one drug company is on the verge of getting this FDA signal. In fact, I think it could happen very soon … That's why I just put together an important video with all the details on this incredible signal — and the stock market winners it's produced. Sincerely, Michael Robinson, Editor Disruptors & Dominators Weiss Ratings | 11780 US Highway 1 | Palm Beach Gardens, FL 33408 If you would like to opt-out of receiving offers from Weiss Ratings please click here.

IMPORTANT NOTICE AND DISCLAIMER Active Trader Media, LLC ("ATD"), the owner of this website (the "Website"), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the "Publications"). The author or authors of those Publications are solely responsible for their contents. ATD has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. ATD will NOT be liable for any loss or damage caused by a reader's reliance on information posted on the Website or contained in the Publications. FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company's financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications. SUBSTANTIAL RISK IN INVESTMENT. Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER Neither ATD nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization. To more fully understand our Website, please review our full disclaimer located at: https://activetraderdaily.com/index.php/disclaimer/ DISCLAIMER: Active Trader Daily is strictly a research publishing firm and much of the information we publish in email and our various websites are obtained from sources we believe to be reliable. You should know that accuracy can never be guaranteed. We do not design our content to meet your personal situation & you need to know we are absolutely not financial advisors and we never, under any circumstance give our users personalized advice. Every single opinion we express herein are those of the publisher and are subject to change without notice. Published content may become outdated and there is no obligation to update any such information. This communication includes advertising material and PAID ADVERTISEMENTS provided to our customers. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Sponsored emails, like this in Active Trader Daily or our other publications, contain paid advertisements and don't necessarily endorse or recommend it to you or any investor. Neither the company nor our affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Proceed at your own risk. Privacy Policy If you wish to contact us, please do not reply to this message but instead e-mail us at info@em.activetraderdaily.com. Replies to this message may not be read or responded to. We are unable to respond to emails and phone calls requesting personal financial advice. Sponsored emails, like this in Active Trader Daily or our other publications, contain paid advertisements and don't necessarily endorse or recommend it to you or any investor. Neither the company nor our affiliates bear responsibility or control over the content of the advertisement and the product or service offered. Proceed at your own risk. If you wish to contact us, please do not reply to this message but instead e-mail us at info@em.activetraderdaily.com. Replies to this message may not be read or responded to. We are unable to respond to emails and phone calls requesting personal financial advice. At Active Trader Daily, it's our mission to create and provide a community that helps you live a more lucrative and enriched life. When Active Trader Daily was established a few years back, we wanted to make the community an inclusive, welcoming table where everyone can come to find investment trends! Over the years, and over 100 thousand combined followers across our social media platforms, we will always aim to get better at what we do every single day! In addition, our primary focus is on our relationship with you. This way every time you decide to visit one of our properties or read one of our relevant articles, you end up getting an idea that takes your investment portfolio to the next level. We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next investment or stock purchase even better than the last! Since we put so much effort into the relationship with you, we hope that any time spent with us is exactly the way you hoped it would be. Because by choosing to go with Active Trader Daily, it's our promise that we provide a community you will love for years and years to come. Now, as much as we care about helping you make the right investments, we also care about your privacy. At Active Trader Daily transparency and the use of data are important and we would like to be as explicit as we can about the use of data collected through our platforms. Active Trader Daily is owned and operated by Active Trader Daily, LLC. We're committed to the right of your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website. What Information Do We Collect? When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site following all compliance standards. For example, you may need to provide the following information: Name Website URL information Email address Home and business phone number In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses securely within our systems. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone. It also explains important information that ensures we won't abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law. Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at info@em.activetraderdaily.com. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website ActiveTraderDaily.com where you can find the latest information regarding data collection and use. If you end up visiting ActiveTraderDaily.com, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. ProTrading Research, LLC operates the Website. This privacy policy has been created to keep you informed about the steps we take once data is acquired. It is regularly updated to meet the needs of a changing technological environment ensuring its relevancy. Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using ActiveTraderDaily.com, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at info@em.activetraderdaily.com. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the "unsubscribe" link located on the bottom of any marketing email. By clicking the link you will be taken to a page where you may unsubscribe from future marketing emails. Your change in status may take up to seventy-two hours to be reflected within our system. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt-out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies. Active Trader Daily 203 N La Salle Street, Suite 2100 | Chicago, IL 60601 Unsubscribe Here